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Summary
Objectives: CCI-779 is an ester of the immunosuppressive agent sirolimus (rapamycin) that causes cell-cycle arrest
at G1 via inhibition of key signaling pathways resulting in inhibition of RNA translation. Antitumor activity has
been demonstrated using cell lines and animal models of malignant glioma. Patients receiving enzyme-inducing
anti-epileptic drugs (EIAEDs) can have altered metabolism of drugs like CCI-779 that are metabolized through the
hepatic cytochrome P450 enzyme system. The objectives of this study were to determine the pharmacokinetic profile
and the maximum tolerated dose of CCI-779 in patients with recurrent malignant gliioma taking EIAEDs. Study
design: The starting dose of CCI-779 was 250 mg intravenously (IV) administered weekly on a continuous basis.
Standard dose escalation was performed until the maximum tolerated dose was established. Toxicity was assessed
using the National Cancer Institute common toxicity criteria. Results: Two of 6 patients treated at the second dose
level of 330 mg sustained a dose-limiting toxicity: grade III stomatitis, grade 3 hypercholesterolemia, or grade
4 hypertriglyceridemia. The maximum tolerated dose was reached at 250 mg IV. Pharmacokinetic profiles were
similar to those previously described, but the area under the whole blood concentration-time curve of rapamycin
was 1.6 fold lower for patients on EIAEDs. Conclusions: The recommended phase II dose of CCI 779 for patients
on enzyme-inducing antiepileptic drugs is 250 mg IV weekly. A phase II study is ongoing to determine the efficacy
of this agent.
Introduction
Treatment options are limited for patients with ma-
lignant glioma recurring despite radiation and adju-
vant chemotherapy with either a nitrosourea or temo-
zolomide [1]. Recent advances in the understanding
of molecular and cytogenetic pathways involved in
gliomagenesis, tumor growth, and invasion have led
to the rational targeting of aberrant molecular path-
ways. A significant proportion of glioblastoma mul-
tiforme (GBM) have altered PTEN gene-suppression
activity [2], which results in the increased activity of
the phosphotidylinositol 3-kinase (PI3K)/Akt pathway.
This in turn activates the mammalian target of ra-
pamycin (mTOR), thereby increasing translation of a
number of key proteins required for cell-cycle progres-
sion. The presence of PTEN gene alterations and the
subsequent activation of the PI3K/Akt/mTOR pathway
have been associated with poor prognosis in anaplastic
astrocytoma (AA), anaplastic oligodendroglioma, and
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GBM [3–5]. Restoration of PTEN function or targeting
of the components of the PI3K/Akt/mTOR pathways
can result in cell-cycle arrest, apoptosis, or reduced
tumorigenicity and are rational targets for clinical
evaluation.
One agent that targets the mTOR pathway is
CCI-779, a dihydroxymethyl propionic acid ester of
the immunosuppressive agent sirolimus (rapamycin,
Rapamune©R ). Rapamycin, a macrolide originally iso-
lated from Streptomyces hygroscopicus, is a potent im-
munosuppressant, and like other natural immunosup-
pressants such as cyclosporin A and FK-506 interacts
with signal-transduction systems that operate in both
normal T cells and tumor cells. These agents bind to a
ubiquitous family of proteins known as immunophilins,
inhibiting their enzymatic activity. Rapamycin binds to
one of these proteins to form a complex that interacts
with mTOR, which results in cell-cycle arrest via inhi-
bition of RNA translation [6–8].
During development and evaluation of rapamycin
and its analogs, physiochemical and pharmaceutical
factors were considered in the selection of an optimum
derivative. The National Cancer Institute, in collabora-
tion with Wyeth Ayerst, examined several derivatives
of rapamycin and selected CCI-779 for further devel-
opment based on in vitro and in vivo data. CCI-779
is lipid soluble and inhibits the growth of a number
of human tumor lines in nude mouse models including
glioblastoma. In addition, 2 preclinical studies reported
the inhibition of growth of PTEN-mutant tumor cells by
CCI-779, both in vitro and in the PTEN ± mouse model
[9–11]. Clinical studies in patients with other solid tu-
mors demonstrated that CCI-779 was well tolerated,
with the major adverse events being myelosuppression,
cutaneous toxicity, nausea/vomiting, diarrhea, and hy-
pertriglyceridemia [6, 12]. The dose of 250 mg once
weekly as a flat dosing schedule was selected for fur-
ther study based on therapeutically achieved drug lev-
els. Based on the preclinical and clinical data outlined
above there was an interest in evaluating this novel
agent in patients with malignant glioma.
There is increasing evidence that brain-tumor pa-
tients receiving P450 enzyme-inducing anti-epileptic
drugs (EIAEDs) have markedly altered pharmacoki-
netics, resulting in accelerated drug metabolism. CCI-
779 and rapamycin are substrates for the cytochrome
P450 isoenzyme 3A4. It is likely that the patients tak-
ing EIAEDs would have increased drug metabolism
and would tolerate a higher dose than patients who are
not taking these agents.
Patients on EIAEDs were enrolled in the phase I
component of this study with dose escalations in ini-
tial cohorts of 3 with standard criteria for escalation.
The primary objectives of this phase I study were to es-
tablish the maximum tolerated dose of CCI-779 in pa-
tients with malignant glioma who are taking EIAEDs
and to define the safety profile of CCI-779 adminis-
tered weekly. Pharmacokinetic (PK) analyses were per-
formed to evaluate the CCI-779 and rapamycin concen-
trations and clearance characteristics and to compare
the parameters of exposure to those of patients not on
EIAEDs (enrolled in phase II of this trial). The phase II
component for the EIAED group will be initiated based
on the maximum tolerated dose (MTD) established in
this phase I study. We report on the results of the phase I
trial in patients on EIAEDs and on the pharmacokinetic
components of the study.
Methods
Patient eligibility
Patients at least 18 years of age participated if they
had histopathologically confirmed recurrent malignant
glioma as shown on neuro-imaging. Participating pa-
tients had relapsed after prior radiation therapy with an
interval of at least 4 weeks from treatment with radio-
therapy, and had not received treatment for more than
3 prior relapses. Patients had a Karnofsky Performance
Status of at least 60 with an estimated survival of greater
than 8 weeks. Their hematologic, renal, and hepatic sta-
tus was within the normal range, levels of cholesterol
were less than 350 mg/dl, and levels of triglyceride
were less than 400 mg/dl, respectively. No exclusions
were made based on gender, race, minority status, or
economic status. Female patients were not pregnant or
nursing, and all patients (both men and women) agreed
to practice birth control during and for 3 months after
the study was completed. Patients or their surrogates
signed a Committee on Human Research institution-
ally approved consent form. Patients did not have any
serious intercurrent illness or disease that obscured or
altered drug metabolism.
Study design
Patients were treated with CCI-779 as a 30-minute IV
infusion weekly with no rest period required. For the
purpose of evaluation, a cycle was defined as every
4 weeks. During the 8th week of treatment patients
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Table 1. Enzyme-inducing and non-enzyme-inducing
anti-epileptic drugs
EIAEDs
















underwent clinical and radiographic tumor re-staging.
Determination of tumor status was made using
standard criteria [13]. Therapy with CCI-779 was
continued as long as the tumor was stable or smaller in
size and the patient was clinically stable or improved.
Treatment continued indefinitely as long as there were
no unacceptable toxicities, patient refusal to continue
participation, or tumor progression. Patients receiving
EIAEDs were treated at an initial dose level of 250 mg
IV weekly, and dose levels of 330, 440, 585, and
780 mg were defined for escalation. Table 1 outlines
the drugs categorized as EIAEDs and non-EIAEDs.
Definition of the maximum tolerated dose
The maximum tolerated dose was based on the toler-
ability observed during the first 4 weeks of treatment.
Standard phase I dose escalations were planned among
groups of 3 patients, with an additional 3 patients added
at the first indication of dose-limiting toxicity. The
maximum tolerated dose of CCI-779 was that dose at
which fewer than one-third of patients experienced a
dose limiting toxicity, i.e., the dose at which 0/3 or
1/6 patients experienced a dose-limiting toxicity with
the next higher dose having at least 2/3 or 2/6 patients
who experienced a dose-limiting toxicity.
Toxicity assessment
Toxicities were graded according to the NCI Common
Toxicity Criteria scale (CTC Version 2.0). If multiple
toxicities were seen, the presence of a dose-limiting
toxicity was based on the most severe toxicity experi-
enced. A dose-limiting toxicity was defined as any of
the following events occurring during the first 4-week
course of treatment of CCI-779 and attributable to the
study drug: any grade 4 hematologic toxicity; any non-
hematologic grade 3 toxicity; or failure to recover from
toxicities to be eligible for re-treatment with CCI-779
within 2 weeks of the last dose of CCI-779 treatment.
Pharmacokinetic evaluation
Sample collection. Whole blood (7 ml) was collected
in EDTA-containing tubes at each of the following
times: baseline (prior to infusion); end of infusion; and
0.5, 1, 1.5, 2, 3, 5, 8, and 24 hours post-administration.
Baseline samples were also obtained on course 1 day
8 and course 2 day 1. The whole blood was transferred
into 2 polypropylene tubes (1 for CCI-779 determina-
tion and 1 for rapamycin) and stored at −70◦C until
analyzed. Whole blood was selected as the biological
matrix for analysis due to CCI-779’s and rapamycin’s
preferential distribution into red blood cells and more
limited storage stability in plasma.
Analytical methods
For the analysis of CCI-779 and rapamycin, 2 separate
high performance liquid chromatography (HPLC) with
electrospray ionization mass spectrometry (LC/ESI-
MS) assays were developed and validated. CCI-779
and the deuterated (d7) CCI-779 internal standard (IS)
as well as rapamycin and its IS (desmethoxyrapa)
were obtained from Wyeth-Ayerst Research (Mon-
mouth Junction, NJ) through Dr. Janet Dancey (Div.
Cancer Treatment Diagnosis Ctr., NCI).
CCI-779 and rapamycin were isolated from whole
blood by liquid-liquid extraction. Briefly, 850 µl of
whole blood was spiked with 100 µl (50 ng) of the
appropriate IS followed by the addition of 7 ml of
1-chlorobutane. After circular rotation for 1 hour, the
samples were centrifuged (10◦C at 3000 RPM ×
15 min) and placed in a −80◦C freezer for 30 min-
utes. The organic layer was separated and evaporated
to dryness under a gentle stream of nitrogen in a
35◦C water bath and reconstituted with 100 µl of mo-
bile phase consisting of 0.05 mM sodium acetate and
0.002% (V/V) acetic acid in methanol pumped at a flow
rate of 0.2 ml/min. Following re-centrifugation for 15
min, 20 µl of sample was injected using a Hewlett
Packard series II 1090 HPLC (Hewlett Packard, Palo
Alto, CA). Separation of CCI-779 was accomplished
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by using a Waters C18 SymmetryTM column (3.5 µm,
21 × 50 mm) preceded by a Waters SentryTM C18
guard column (3.5 µm, 2.1×10 mm) (Waters Corpora-
tion, Milford, MA). A Phenomenex C6 column (3 µm,
150×200 mm) preceded by a Phenomenex SecurityTM
C5 guard column (3 µm, 2 × 4 mm) (Phenomenex,
Torrance, CA) was used for the separation of ra-
pamycin. After separation, the sample was directly
flushed into the API electrospray interface (Finnigan
LCQTM spectrometer (MS), San Jose, CA). The MS
settings were: sheath gas (N2) flow rate–66 arb; capil-
lary voltage–23 V; auxiliary gas (He) flow rate–27 arb;
capillary temperature–230◦C; spray voltage–5.5 kV;
and tubes lens offset–10 V.
In the MS/MS mode, the collision energy was 42%.
For peak identification, full-scan mass spectra were
acquired in the positive ion mode. The MS/MS scan
range for CCI-779 was 950–1100, and 600–1100 for
rapamycin. Selected ion monitoring (SIM) was used
for the determination of the sodium adducts [M +
Na] and the compound’s respective fragment ion: CCI-
779 (m/z 1052.3 → 1020.4), d7-CCI-779 (m/z 1057.3
→ 1027.4), and rapamycin (m/z 936.5 → 904.3),
desmethoxy rapamycin (m/z 906.4 → 874.4). Data ac-
quisition and integration of the chromatograms were
performed using XcaliberTM software (Version 1.0,
Finnigan, San Jose, CA). The chromatographic data
were analyzed by linear least square regression with
a weighting factor of 1/×2 generating an eight-point
calibration curve of area ratios for CCI-779 and ra-
pamycin. Unknown concentrations were determined
by reverse prediction against the standard curve. The
calibration curves for both CCI-779 and rapamycin
were linear (R2 > 0.99) over the range from 6.58 to
526.5 ng/ml. End-of-infusion samples for CCI-779
were diluted 1:100 into the linear range of the cali-
bration curve. Each sample was analyzed in duplicate.
Samples were repeated if the variation between sam-
ples was greater than 16%. The interday precision (CV)
for CCI-779 was 1.7, 4.38, and 10.5%, respectively for
the low, medium, and high quality control (QC) sam-
ples. The interday accuracy (bias) was within ±4.7.
The interday precision for rapamycin was 12.21, 6.1,
and 6.73%, respectively for the low, medium, and high
QC samples. The interday accuracy was within ±5.9%.
Pharmacokinetic analyses
CCI-779 and rapamycin whole blood concentrations
were analyzed by non-compartmental methods. The
time intervals relative to the start of the CCI-779 infu-
sion and the actual sample times were used for the deter-
mination of time to peak (tmax) and the area under the
whole blood concentration-time curves (AUC). Peak
concentrations (CPmax) were determined by inspec-
tion of each individual’s whole blood concentration-
versus-time curve. Elimination rate constants were es-
timated by linear regression of the last 2 data points
on the terminal log linear portion of the concentration-
time curve. Terminal half-lives (t1/2) were calculated
by dividing 0.693 by the elimination rate constants. The
AUC was calculated using the linear trapezoidal rule up
to the last measurable data point (for AUC0-24), then
extrapolated to infinity (AUC). The systemic clearance
(CL) for CCI-779 was determined by dividing the dose
by the AUC. A metabolic ratio estimated as the ratio of
the AUCrap to the AUCCCI was used as a measure of the
relative extent of conversion of CCI-779 to rapamycin.
Results
Clinical results
Twelve patients (6 males/6 females) were enrolled. Me-
dian age was 52 years (range 39–63 years) and the
median Karnofsky Performance Scale was 90. Patient
characteristics are shown in Table 2. Two dose levels
were evaluated. At the 250 mg level, 2 patients were on
single-agent dilantin, 1 on tegretol, 1 on Phenobarbi-
tal, and 2 on combination agents (1 on Phenobarbital,
Keppra, and dilantin and 1 on Trileptal and Neuron-
tin). At the 330 mg dose level, all patients were on
monotherapy–3 on dilantin, 2 on tegretol, and 1 on car-
batrol. There was 1/6 dose-limiting toxicity at the first
dose level of 250 mg consisting of grade III hyper-
triglyceridemia. Two of 6 patients treated at the second
dose level of 330 mg sustained a dose-limiting toxic-
ity: 1 patient developed grade III stomatitis and another
grade 3 hypercholesterolemia as well as grade 4 hyper-
triglyceridemia that required a delay of more than 2
weeks before retreatment (Table 3). The maximum tol-
erated dose was therefore established at 250 mg IV
weekly for patients on enzyme-inducing antiepileptic
agents. There is limited information on the toxicity pro-
files on the 12 patients in this study beyond the first
course. There were no grade IV toxicities seen and the
grade III toxicities are shown in Table 4 with informa-
tion provided based on the course number. The phase
II study will provide more information on cumulative
and long-term toxicity.
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Anaplastic astrocytoma 3 25
Glioblastoma multiforme 9 75
Therapy for prior relapses
1 6 50
2 6 50
Table 3. Toxicity observed in the phase I study (n = 12),
using the National Cancer Institute Common Toxicity Grading
System
Dose level n Dose limiting toxicity
250 mg 6 1 grade III hypertriglyceridemia
330 mg 6 1 grade III stomatitis
1 grade III hypercholesterolemia, grade IV
hypertriglyceridemia, and delay of > 2
weeks before retreatment
Table 4. Grade III toxicities seen beyond course 1 for the
2 cohorts
250 mg dose level cohort




330 mg dose level cohort
Course no. n Grade III toxicity
2 1 Headache∗
Hypophosphatemia∗
*These toxicities were experienced after a dose reduction
from 330 to 250 mg for the second course.
In this small cohort of 12 patients, no partial or
complete responses were observed. There were 4/6 pa-
tients in the 250 mg dose level with stabilization of
their disease, with median progression-free survival of
10 weeks. The efficacy of this agent is being evalu-
ated in the ongoing phase II study in patients with re-
current malignant glioma on and off enzyme-inducing
antiepileptic agents.
Pharmacokinetic results
A typical whole blood concentration-versus-time curve
at the 250 mg dose level for CCI-779 and rapamycin is
displayed in Figure 1. CCI-779 was rapidly converted
to rapamycin. The pharmacokinetic results for CCI-
779 and rapamycin are shown in Table 5. Comparison
of the pharmacokinetic parameters at the 250 mg dose
level between 2 groups (non-EIAEDs vs. EIAEDs; pa-
tients not on EIAEDs were being treated on a con-
current phase II study) showed no difference except
for the AUCs for rapamycin. The rapamycin AUC was
1.6-fold lower for patients receiving EIAEDs. A pro-
portionate increase in blood concentrations or AUCs
was not observed in the EIAED group for either CCI-
779 or rapamycin when escalating the dose from 250–
330 mg. In fact it was lower for CCI-779 at the higher
dose level versus the lower dose. Although a pharma-
cogenetic explanation may account for this variability,
it is probably best explained by a random finding in
a small number of patients with only 1 increment for
comparison. Baseline levels for CCI-779 on course 1
day 8 or course 2 day 1 were nondetectable. In con-
trast, baseline levels for rapamycin were observed in
the majority of patients. The concomitant medications
that patients received that may also be metabolized
by the CYP3A4 system were reviewed. Seven out of
12 patients were on concomitant steroids (3 in the 250
dose-level group and 4 in the 330 dose-level group,
respectively). Two patients in the 250 cohort were on
diflucan and 1 was on metaclopramide.
Pharmacokinetic profiles for patients in the phase II
component of the study continue to be assessed.
Discussion
The insight into the relevance of the P13K/Akt/mTOR
pathway in the proliferation of tumors has generated
several rational targeted therapies. Wortmannin and
LY294002 are inhibitors of PI3K, while rapamycin,
RAD001, and CCI-779 inhibit the activity of mTOR
[14–16]. CCI-779, an ester of rapamycin, was selected
for further evaluation based on its more favorable phar-
maceutical profile over other clinical leads evaluated.
Based on preclinical data of CCI-779 and its potential
anti-glioma activity, the efficacy of this agent is being
evaluated in a concurrent phase II study in patients with
recurrent malignant glioma who are not on concomi-
tant antiepileptics that may induce the CYP450 hepatic
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Table 5. Pharmacokinetic Parameters of CCI-779 and Rapamycin
CCI-779 Rapamycin
Means Dose Cmaxa t1/2† AUCc CLd CL Vdsse Cmax t1/2† AUC AUC ratio Trough 24 h Baseline
(±SD) (mg) (µg/ml) (h)b (µg × h/ml) (L/h) (L/h/m2) (L) (ng/ml) (h) (µg × h/ml) Rap:CCI Post (ng/ml) 168 h ng/ml
Group 250 6.2 9.0 6.1 47 (18) 24 308.68 310 50 15.1 2.8 137 15
A∗ (5.7) (3.8) (2.9) (8.9) (175) (120) (23) (3.7) (1.3) (24) (6.9)
(n = 4)
Group 250 5.2 8.5 5.7 50 25 671.10 182 35 9.3 1.9 111 7
B∗∗ (4.9) (2.7) (2.7) (20) (7.0) (307 (45) (13) (2.2) (0.9) (18) (n = 1)
(n = 3)
Group 330 2.2 10.0 3.3 103 48 781.61 278 24 9.1 2.8 132 13
B (n = 3) (0.9) (3.4) (0.4) (13) (2.6) (401) (105) (5.5) (1.8) (0.6) (33) (n = 1)
∗non-EIAEDs f ; ∗∗EIAEDs; †Harmonic mean.
aCmax: maximum concentration;bt1/2: half life; cAUC: area under the curve; d CL: clearance; eVdss: volume of distribution; f EIAEDs: enzyme
inducing anti-epileptic agents.
Figure 1. Typical whole blood concentration-time curve for CCI-779 and rapamycin following the administration of CCI-779 IV over
30 minutes.
enzyme system. Because CCI-779 and rapamycin are
metabolized by this enzyme system and concurrent use
of these agents may result in increased clearance of
CCI-779, we sought to establish the appropriate phase
II dose in patients on enzyme-inducing agents. The
general observation of a higher tolerated dose in pa-
tients on enzyme-inducing antiepileptic agents was es-
tablished for other agents used in the therapy of malig-
nant glioma including the chemotherapeutic agents pa-
clitaxel [17] and irinotecan [18] and the farnesyl trans-
ferase inhibitor R115777 [19].
In this phase I study, the maximum tolerated dose
of CCI-779 in patients on enzyme inducing agents was
established at 250 mg IV weekly with dose-limiting
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toxicities consisting of previously observed but man-
ageable elevation of lipid profile, hypophosphotemia,
and anemia. The dose selected in the phase II study
for glioma patients not on EIAEDs was 250 mg, which
had to be decreased to 170 mg because of excessive
toxicity, mainly stomatitis. The recommended phase II
dose of 250 mg for the patients with glioma on EIAEDs
is therefore higher than for those not on EIAEDs. For
non-glioma patients studied during other trials, prelim-
inary results for the weekly dose schedule showed that
doses less than 220 mg/m2/week were feasible [20],
and that at the 250 mg-weekly dose toxicities were usu-
ally grade II in nature [21, 22]. Final reports of these
studies are not yet available.
Escalation beyond the starting dose of 250 mg was
not tolerated. This finding may not be surprising given
the results of the pharmacokinetic data generated from
this study. CCI-779 is converted to rapamycin that
is itself metabolized by the same CYP450 enzyme
system and can be associated with its own spectrum of
side effects. The toxicities encountered therefore may
have reflected the additive and/or cumulative effects of
both drugs. The mean whole blood terminal disposition
half-life for rapamycin is reportedly 82 ± 12 hours
[23]. The terminal half-life for rapamycin observed
in our study averaged 42 ± 24 hours. The sampling
schedule for our trial extended only to 24 hours post-
dose and the number of patients evaluated was small.
Therefore, our observed rapamycin half-life is proba-
bly underestimated. This is supported by the significant
levels of rapamycin remaining at 24 hours post-dose
and detection of baseline levels prior to the next weekly
dose. The low baseline concentrations of rapamycin
would not be expected to result in any significant
accumulation from week to week. More detailed
pharmacokinetic data will be generated in the phase II
study.
Although dose escalation was not possible because
of side effects, the conversion of CCI-779 to ra-
pamycin is of clinical significance. The administration
of CCI-779 intravenously allows for the delivery
of a potentially active antitumor agent that is also
converted to another active antitumor agent. Eshleman
et al. showed that incubation with 100 mM of CCI-779
(91.4 ng/ml) for 72 hours significantly inhibited the
proliferation of U87 malignant glioma cells [24]. Both
the parent drug and its metabolite have a spectrum of
side effects, some of which overlap. This paradigm is
distinct from the administration of a classic inactive
“pro-drug” that requires activation or the administra-
tion of an active agent that is subsequently degraded to
an inactive form. This emphasizes that the subsequent
early clinical evaluation of new agents must take into
consideration not only the pharmacokinetic data but
also the biochemical properties of the agent and its
metabolites. One of the secondary objectives of the
phase II study will be the assessment of toxicity and
tolerability of this agent in a larger patient population.
Because of the risk of immunosuppression and the
common concomitant use of steroids, opportunistic
infections may be seen at a higher rate in phase II
studies. A recent pubication by Peralba et al. suggests
the possible use of p70(s6) kinase activity as a
surrogate marker of drug activity [25]. Further work
evaluating this marker needs to be done. In addition,
there may be a role for combination CCI-779/standard
cytotoxic chemotherapy in the management of
glioma.
Conclusions
The maximum tolerated dose of CCI-779 administered
IV on a weekly intravenous schedule to patients with
recurrent malignant glioma on enzyme inducing
antiepileptic drugs was 250 mg. Agents such as
paclitaxel and irinotecan that are metabolized via
the CYP450 pathway have altered clearance and the
established phase II dose of these agents for patients on
enzyme-inducing agents was substantially higher than
for those who were not. In contrast, although CCI-779
is also metabolized via this pathway, its conversion
to rapamycin, which not only has possible antitumor
effect but also potential toxicity, may have precluded
escalation beyond the level seen for those patients who
were not taking enzyme-inducing agents. This em-
phasizes the importance of biochemical information
as well as the pharmacokinetic and pharmacodynamic
studies that need to be considered in early clinical
studies in order to characterize the effect of the agent
and its metabolites on patients. The phase II study
in patients with recurrent malignant glioma on and
off enzyme-inducing antiepileptic drugs is ongoing
to further characterize the pharmacokinetics, safety
profile, and efficacy of CCI-779.
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